- Peanut allergy is a severe and potentially life-threatening food allergy that affects a significant portion of the global population, particularly children. It often requires strict avoidance of peanuts and prompt emergency treatment in case of accidental exposure
- The demand for Peanut Allergy Treatment is primarily fueled by improved diagnostic capabilities leading to earlier identification, increased patient and caregiver education, and a robust pipeline of novel immunotherapies aimed at desensitization or prevention.
- North America dominates the Peanut Allergy Treatment Market with the largest revenue share of 40.01% in 2024, characterized by a high prevalence of peanut allergies, advanced healthcare infrastructure, and significant investments in food allergy research and development
- The U.S. is experiencing substantial growth in Peanut Allergy Treatment, particularly in specialized allergy clinics and academic medical centers, driven by regulatory approvals for oral immunotherapies and strong patient advocacy
- Asia-Pacific is expected to be the fastest-growing region in the Peanut Allergy Treatment Market during the forecast period due to increasing awareness, improving diagnostic facilities, and a rising incidence of food allergies in countries with large populations like China and India
- The Injectable Epinephrine segment dominates the Peanut Allergy Treatment Market with a market share of 37.32% in 2024, driven by its established efficacy in desensitizing patients to peanut allergens and its potential to significantly reduce the risk of severe reactions
